The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.
Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)
Closing Date of Accrual
30 June 2019
A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC
The journey to becoming the 200th participant for the
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292